$CRNX
Crinetics Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023060254 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $346.0K
YoY Change -100.0% -24.45%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.08M $15.48M
YoY Change 51.48% 29.81%
% of Gross Profit
Research & Development $45.58M $43.84M
YoY Change 23.22% 37.05%
% of Gross Profit
Depreciation & Amortization $262.0K $280.0K
YoY Change -6.43% 12.9%
% of Gross Profit
Operating Expenses $62.66M $59.32M
YoY Change 29.82% 35.1%
Operating Profit -$58.98M
YoY Change 35.72%
Interest Expense $29.82M $2.530M
YoY Change -2.45% 72.93%
% of Operating Profit
Other Income/Expense, Net -$23.06M $2.516M
YoY Change -17.66% 64.55%
Pretax Income -$55.90M -$56.46M
YoY Change 24.24% 34.67%
Income Tax
% Of Pretax Income
Net Earnings -$60.10M -$57.46M
YoY Change 33.58% 37.05%
Net Earnings / Revenue -16606.36%
Basic Earnings Per Share -$1.01
Diluted Earnings Per Share -$0.89 -$1.01
COMMON SHARES
Basic Shares Outstanding 66.80M 54.69M
Diluted Shares Outstanding 56.81M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $129.0M $449.9M
YoY Change -58.57% 22.14%
Cash & Equivalents $54.90M $142.8M
Short-Term Investments $74.09M $307.1M
Other Short-Term Assets $1.578M $3.521M
YoY Change -37.75% 113.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables $90.00K
Total Short-Term Assets $574.2M $575.8M
YoY Change 66.33% 52.19%
LONG-TERM ASSETS
Property, Plant & Equipment $10.88M $9.764M
YoY Change 210.89% 173.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $470.0K $4.700M
YoY Change
Other Assets $2.000M $2.000M
YoY Change 5305.41% 42.96%
Total Long-Term Assets $61.20M $65.78M
YoY Change 775.29% 903.16%
TOTAL ASSETS
Total Short-Term Assets $574.2M $575.8M
Total Long-Term Assets $61.20M $65.78M
Total Assets $635.4M $641.5M
YoY Change 80.41% 66.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.548M $5.842M
YoY Change -4.87% -0.6%
Accrued Expenses $35.34M $33.00M
YoY Change 89.99% 101.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.94M $40.46M
YoY Change 58.5% 64.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $52.31M $53.30M
YoY Change 543.75% 495.4%
Total Long-Term Liabilities $52.31M $53.30M
YoY Change 543.75% 495.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.94M $40.46M
Total Long-Term Liabilities $52.31M $53.30M
Total Liabilities $96.25M $93.79M
YoY Change 168.49% 179.9%
SHAREHOLDERS EQUITY
Retained Earnings -$653.7M -$593.6M
YoY Change 48.84% 50.58%
Common Stock $253.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $539.1M $547.7M
YoY Change
Total Liabilities & Shareholders Equity $635.4M $641.5M
YoY Change 80.41% 66.68%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$60.10M -$57.46M
YoY Change 33.58% 37.05%
Depreciation, Depletion And Amortization $262.0K $280.0K
YoY Change -6.43% 12.9%
Cash From Operating Activities -$38.52M -$41.34M
YoY Change 9.4% 7.44%
INVESTING ACTIVITIES
Capital Expenditures $935.0K $3.500M
YoY Change 241.24% -613.2%
Acquisitions
YoY Change
Other Investing Activities -$86.37M -$189.8M
YoY Change -332.64% -2629.18%
Cash From Investing Activities -$87.31M -$193.3M
YoY Change -336.91% -2933.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 37.93M 337.9M
YoY Change 32878.26% 31301.49%
NET CHANGE
Cash From Operating Activities -38.52M -41.34M
Cash From Investing Activities -87.31M -193.3M
Cash From Financing Activities 37.93M 337.9M
Net Change In Cash -87.90M 103.2M
YoY Change -5091.37% -437.6%
FREE CASH FLOW
Cash From Operating Activities -$38.52M -$41.34M
Capital Expenditures $935.0K $3.500M
Free Cash Flow -$39.45M -$44.84M
YoY Change 11.19% 18.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001658247
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38583
dei Entity Registrant Name
EntityRegistrantName
Crinetics Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3744114
dei Entity Address Address Line1
EntityAddressAddressLine1
10222 Barnes Canyon Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Bldg. #2
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
450-6464
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CRNX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66799257
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142795000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32672000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
411858000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
301753000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21107000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10759000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
575760000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
345184000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9764000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3500000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
48042000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1486000
CY2023Q3 us-gaap Derivative Assets
DerivativeAssets
0
CY2022Q4 us-gaap Derivative Assets
DerivativeAssets
668000
CY2023Q3 crnx Investment In Radionetics
InvestmentInRadionetics
4671000
CY2022Q4 crnx Investment In Radionetics
InvestmentInRadionetics
0
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1300000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1301000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2000000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
37000
CY2023Q3 us-gaap Assets
Assets
641537000
CY2022Q4 us-gaap Assets
Assets
352176000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21935000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15351000
CY2023Q3 crnx Accrued Compensation And Related Expense
AccruedCompensationAndRelatedExpense
12877000
CY2022Q4 crnx Accrued Compensation And Related Expense
AccruedCompensationAndRelatedExpense
9081000
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
1662000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
2240000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3989000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1051000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
40463000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27723000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48182000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2024000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5144000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6101000
CY2023Q3 us-gaap Liabilities
Liabilities
93789000
CY2022Q4 us-gaap Liabilities
Liabilities
35848000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66708000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66708000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53877000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53877000
CY2023Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
1142218000
CY2022Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
759432000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-865000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3931000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-593605000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-439173000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
547748000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
316328000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
641537000
us-gaap Net Income Loss
NetIncomeLoss
-154432000
us-gaap Net Income Loss
NetIncomeLoss
-118927000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
352176000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
346000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
458000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4013000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4028000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43839000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31987000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
122947000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93234000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15484000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11925000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41016000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31120000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
59323000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
43912000
us-gaap Operating Expenses
OperatingExpenses
163963000
us-gaap Operating Expenses
OperatingExpenses
124354000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-58977000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43454000
us-gaap Operating Income Loss
OperatingIncomeLoss
-159950000
us-gaap Operating Income Loss
OperatingIncomeLoss
-120326000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2569000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1500000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6714000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2413000
CY2023Q3 crnx Other Income Expense
OtherIncomeExpense
-53000
CY2022Q3 crnx Other Income Expense
OtherIncomeExpense
29000
crnx Other Income Expense
OtherIncomeExpense
-199000
crnx Other Income Expense
OtherIncomeExpense
-35000
CY2023Q3 crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
0
CY2022Q3 crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
0
crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
0
crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
31000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2516000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1529000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6515000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2409000
CY2023Q3 crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
56461000
CY2022Q3 crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
41925000
crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
153435000
crnx Loss Before Equity Method Investment
LossBeforeEquityMethodInvestment
117917000
CY2023Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
-997000
CY2022Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
us-gaap Gain Loss On Investments
GainLossOnInvestments
-997000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-1010000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-57458000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41925000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.32
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56808000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56808000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53768000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53768000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55003000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55003000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51356000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51356000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
840000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1391000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3066000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4628000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56618000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43316000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-151366000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123555000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
254116000
CY2023Q3 crnx Transaction Cost On Issuance Of Common Stock
TransactionCostOnIssuanceOfCommonStock
21500000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
328501000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10700000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11049000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
840000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-57458000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
547748000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
316328000
crnx Transaction Cost On Issuance Of Common Stock
TransactionCostOnIssuanceOfCommonStock
21800000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
339812000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1123000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12531000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29320000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3066000
us-gaap Net Income Loss
NetIncomeLoss
-154432000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
547748000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
386165000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1089000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7434000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1391000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-41925000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
351372000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
331944000
crnx Transaction Cost On Issuance Of Common Stock
TransactionCostOnIssuanceOfCommonStock
7800000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
117242000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
813000
crnx Vesting Of Shares Of Common Stock Value Subject To Repurchase
VestingOfSharesOfCommonStockValueSubjectToRepurchase
2000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4606000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20320000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4628000
us-gaap Net Income Loss
NetIncomeLoss
-118927000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
351372000
us-gaap Net Income Loss
NetIncomeLoss
-154432000
us-gaap Net Income Loss
NetIncomeLoss
-118927000
us-gaap Share Based Compensation
ShareBasedCompensation
29320000
us-gaap Share Based Compensation
ShareBasedCompensation
20320000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
836000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
703000
crnx Non Cash Lease Expense
NonCashLeaseExpense
425000
crnx Non Cash Lease Expense
NonCashLeaseExpense
298000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2687000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-385000
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-997000
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-1010000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
0
crnx Change In Valuation Of Derivative Assets
ChangeInValuationOfDerivativeAssets
31000
crnx Noncash License Revenues
NoncashLicenseRevenues
2000000
crnx Noncash License Revenues
NoncashLicenseRevenues
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8368000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1052000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10457000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6911000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
1535000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
-8972000
crnx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-811000
crnx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-691000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-127792000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79998000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
354806000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
296256000
crnx Purchase Of Stock Investment
PurchaseOfStockInvestment
5000000
crnx Purchase Of Stock Investment
PurchaseOfStockInvestment
0
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
250454000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
86805000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3753000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1382000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-113105000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-210833000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
21800000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
7800000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
340267000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117242000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10752000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4606000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
351019000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
121848000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
110122000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-168983000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33973000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201195000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144095000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32212000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142795000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30912000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
1300000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1300000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144095000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32212000
crnx Stock Received Under Licensing Arrangement
StockReceivedUnderLicensingArrangement
2000000
crnx Stock Received Under Licensing Arrangement
StockReceivedUnderLicensingArrangement
0
crnx Exercise Of Derivative Asset For Investment In Radionetics Common Stock
ExerciseOfDerivativeAssetForInvestmentInRadioneticsCommonStock
668000
crnx Exercise Of Derivative Asset For Investment In Radionetics Common Stock
ExerciseOfDerivativeAssetForInvestmentInRadioneticsCommonStock
0
crnx Change In Unvested Stock Liability
ChangeInUnvestedStockLiability
0
crnx Change In Unvested Stock Liability
ChangeInUnvestedStockLiability
2000
crnx Purchase Of Shares Pursuant To Employee Stock Purchase Plan
PurchaseOfSharesPursuantToEmployeeStockPurchasePlan
1123000
crnx Purchase Of Shares Pursuant To Employee Stock Purchase Plan
PurchaseOfSharesPursuantToEmployeeStockPurchasePlan
813000
crnx Right Of Use Assets Obtained In Exchange For Lease Obligation
RightOfUseAssetsObtainedInExchangeForLeaseObligation
46981000
crnx Right Of Use Assets Obtained In Exchange For Lease Obligation
RightOfUseAssetsObtainedInExchangeForLeaseObligation
0
crnx Lease Incentive Obtained In Exchange For Lease Obligation
LeaseIncentiveObtainedInExchangeForLeaseObligation
2925000
crnx Lease Incentive Obtained In Exchange For Lease Obligation
LeaseIncentiveObtainedInExchangeForLeaseObligation
0
crnx Options Exercise Receivable
OptionsExerciseReceivable
1779000
crnx Options Exercise Receivable
OptionsExerciseReceivable
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
455000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
427000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
60000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-593600000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
554700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company’s condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s condensed consolidated financial statements relate to accrual of research and development expenses, valuation of stock-based awards, fair values of financial instruments, revenue recognition, investment in Radionetics, and the assumptions underlying the determination of the estimated incremental borrowing rate for the determination of the Company’s operating lease right-of-use assets. Estimates are based on historical experiences or on forecasts, including information received from third parties and various other factors that the Company believes are reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13551000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9336000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
412723000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
53000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
918000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
411858000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
305684000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3943000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
301753000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
292094000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
291253000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
246276000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
243542000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
120629000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
120605000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
59408000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
58211000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
412723000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
411858000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
305684000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
301753000
CY2023Q3 crnx Available For Sale Investment Securities Less Than12 Months Fair Market Value
AvailableForSaleInvestmentSecuritiesLessThan12MonthsFairMarketValue
227776000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
151000
CY2023Q3 crnx Available For Sale Investment Securities More Than12 Months Fair Value
AvailableForSaleInvestmentSecuritiesMoreThan12MonthsFairValue
79364000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
767000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
307140000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
918000
CY2022Q4 crnx Available For Sale Investment Securities Less Than12 Months Fair Market Value
AvailableForSaleInvestmentSecuritiesLessThan12MonthsFairMarketValue
196489000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
2151000
CY2022Q4 crnx Available For Sale Investment Securities More Than12 Months Fair Value
AvailableForSaleInvestmentSecuritiesMoreThan12MonthsFairValue
82147000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
1792000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
278636000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
3943000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q3 crnx Prepaid Clinical Costs
PrepaidClinicalCosts
3052000
CY2022Q4 crnx Prepaid Clinical Costs
PrepaidClinicalCosts
2567000
CY2023Q3 crnx Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
1606000
CY2022Q4 crnx Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
2293000
CY2023Q3 crnx Foreign Tax Incentive Receivable Current
ForeignTaxIncentiveReceivableCurrent
962000
CY2022Q4 crnx Foreign Tax Incentive Receivable Current
ForeignTaxIncentiveReceivableCurrent
937000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1289000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
939000
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
2622000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1353000
CY2023Q3 crnx Due From Radionetics Current
DueFromRadioneticsCurrent
98000
CY2022Q4 crnx Due From Radionetics Current
DueFromRadioneticsCurrent
135000
CY2023Q3 crnx Landlord Improvements Receivable
LandlordImprovementsReceivable
6178000
CY2022Q4 crnx Landlord Improvements Receivable
LandlordImprovementsReceivable
605000
CY2023Q3 crnx Option Exercise Receivable
OptionExerciseReceivable
1779000
CY2022Q4 crnx Option Exercise Receivable
OptionExerciseReceivable
0
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3521000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1930000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21107000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10759000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14639000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7584000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4875000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4084000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48182000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
400000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9764000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3500000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5842000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6883000
CY2023Q3 crnx Accrued Clinical Costs
AccruedClinicalCosts
3669000
CY2022Q4 crnx Accrued Clinical Costs
AccruedClinicalCosts
1921000
CY2023Q3 crnx Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
3101000
CY2022Q4 crnx Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
4043000
CY2023Q3 crnx Accrued Outside Services And Professional Fees
AccruedOutsideServicesAndProfessionalFees
2908000
CY2022Q4 crnx Accrued Outside Services And Professional Fees
AccruedOutsideServicesAndProfessionalFees
1810000
CY2023Q3 crnx Accrued Landlord Improvements2
AccruedLandlordImprovements2
5424000
CY2022Q4 crnx Accrued Landlord Improvements2
AccruedLandlordImprovements2
359000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
991000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
335000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21935000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15351000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
689000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5587000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7501000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6829000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7034000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
56985000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
84625000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
32454000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
52171000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3989000
us-gaap Operating Lease Cost
OperatingLeaseCost
900000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Cost
OperatingLeaseCost
900000
crnx Schedule Of Deferred Revenue Components
ScheduleOfDeferredRevenueComponents
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue consisted of the following (</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.827%;"></td> <td style="width:1.001%;"></td> <td style="width:1%;"></td> <td style="width:10.012%;"></td> <td style="width:1%;"></td> <td style="width:1.001%;"></td> <td style="width:1%;"></td> <td style="width:11.013%;"></td> <td style="width:1%;"></td> <td style="width:1.001%;"></td> <td style="width:1%;"></td> <td style="width:10.012%;"></td> <td style="width:1%;"></td> <td style="width:1.001%;"></td> <td style="width:1%;"></td> <td style="width:10.132%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three months ended September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine months ended September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenues at beginning of period</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,152</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,431</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,341</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unearned revenue from cash received during the period, excluding amounts recognized as revenue during the period</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,972</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue recognized that was included in deferred revenues as of the beginning of the period</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">346</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">459</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,535</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at end of period</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,806</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,972</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,806</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,972</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less deferred revenue, current</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,662</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,320</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,662</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,320</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue, non-current</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,144</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,652</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,144</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,652</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 crnx Upfront Payment As License Revenue
UpfrontPaymentAsLicenseRevenue
300000
crnx Upfront Payment As License Revenue
UpfrontPaymentAsLicenseRevenue
1500000
crnx Upfront Payment As Deferred Revenue
UpfrontPaymentAsDeferredRevenue
13000000
CY2022Q3 crnx Upfront Payment As License Revenue
UpfrontPaymentAsLicenseRevenue
500000
crnx Upfront Payment As License Revenue
UpfrontPaymentAsLicenseRevenue
4000000
crnx Upfront Payment As Deferred Revenue
UpfrontPaymentAsDeferredRevenue
13000000
CY2019Q3 crnx Maximum Amount Of Common Stock Preferred Stock Debt Securities Warrants And Units To Be Issued
MaximumAmountOfCommonStockPreferredStockDebtSecuritiesWarrantsAndUnitsToBeIssued
300000000
dei Document Effective Date
DocumentEffectiveDate
2019-08-29
CY2019Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75000000
CY2021Q3 crnx Maximum Share Of Common Stock Preferred Stock Debt Securities Warrants And Units To Be Issued
MaximumShareOfCommonStockPreferredStockDebtSecuritiesWarrantsAndUnitsToBeIssued
851306
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
150000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9757329
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4027897
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.28
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
710020
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
17.65
crnx Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited And Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndExpired
611685
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
20.69
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12463521
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
144674000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12463521
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
144674000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5137282
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
66733000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5600000
CY2023Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2022Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11049000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7434000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29320000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20320000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32344371
CY2023Q3 crnx Additional Sales Milestones
AdditionalSalesMilestones
15000000
CY2023Q3 crnx Due From Radionetics Current
DueFromRadioneticsCurrent
100000
CY2022Q4 crnx Due From Radionetics Current
DueFromRadioneticsCurrent
100000
CY2023Q3 crnx Reimbursement Earned
ReimbursementEarned
21000
crnx Reimbursement Earned
ReimbursementEarned
53000
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-060254-index-headers.html Edgar Link pending
0000950170-23-060254-index.html Edgar Link pending
0000950170-23-060254.txt Edgar Link pending
0000950170-23-060254-xbrl.zip Edgar Link pending
crnx-20230930.htm Edgar Link pending
crnx-20230930.xsd Edgar Link pending
crnx-ex10_1.htm Edgar Link pending
crnx-20230930_cal.xml Edgar Link unprocessable
crnx-20230930_def.xml Edgar Link unprocessable
crnx-20230930_lab.xml Edgar Link unprocessable
crnx-20230930_pre.xml Edgar Link unprocessable
crnx-20230930_htm.xml Edgar Link completed
crnx-ex31_1.htm Edgar Link pending
crnx-ex31_2.htm Edgar Link pending
crnx-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending